Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD

NCT01616927 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT01616927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01616927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD
Lead sponsor
University Medical Center Groningen
Phase
Phase 3
Overall status
Unknown status
Start date
June 30, 2012
Completion date
December 31, 2017
Enrollment
300 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney disease (adpkd)